You are accessing a medical content website
Are you a health professional?

 
Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2017;70:1074-81 - Vol. 70 Num.12 DOI: 10.1016/j.rec.2017.02.041

Real Structural Valve Deterioration of the Mitroflow Aortic Prosthesis: Competing Risk Analysis

Rocío Díaz a,, Daniel Hernández-Vaquero a, Jacobo Silva a,b, Isaac Pascual a, Jesús M. de la Hera a, Víctor León a, María Martín a, Vicente Barriales a, Santiago Colunga a, Raquel del Valle a, César Morís a,b

a Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
b Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain

Refers to

Early Structural Valve Deterioration of the Mitroflow Aortic Bioprosthesis: Will the New Anticalcification Treatment Change Anything?
Arnau Blasco-Lucas, José Manuel Rabasa, Daniel Ortiz, Albert Miralles
Rev Esp Cardiol. 2017;70:1152
Full text - PDF

Keywords

Aortic valve replacement. Bioprosthesis. Structural valve deterioration.

Abstract

Introduction and objectives

The Mitroflow aortic prosthesis is a bovine pericardial bioprosthesis specially designed to increase the valve area in relation to its size. There is controversy regarding the pattern of structural valve deterioration (SVD). Our aim was to determine the cumulative incidence of SVD, risk factors influencing its occurrence, and its impact on mortality.

Methods

A total of 1028 patients were clinically and echocardiographically followed up. Because the study population was elderly and had heart disease, we used a competing risk analysis.

Results

The percentage of patients with SVD at 5 years was 4.22% (95%CI, 2.96-5.81) and was 15.77% at 8 years (95%CI, 12.46-19.43). The incidence was higher for small valves (19 mm and 21 mm) reaching 6.43% at 5 years (95%CI, 4.48-8.84) and 20.06% at 8 years (95%CI, 15.53-25.01). Severe patient-prosthesis mismatch (PPM) influenced the incidence of SVD (sHR, 3.53; 95%CI, 2.20-5.66; P < .001) but moderate PPM had no impact. The most powerful predictor of mortality was the presence of SVD (HR, 4.59; 95%CI, 2.91-7.22; P < .001).

Conclusions

This study used a definition based on the increase in the transprosthetic gradient and found a higher incidence of SVD of the Mitroflow prosthesis than that reported by other series, especially for sizes 19 mm and 21 mm and in patients with severe PPM. The incidence of SVD increased exponentially from the fifth year after implantation and its occurrence led to a 4.5-fold increase in the risk of death.

Article

You can access the full text of this article:

Members of the Spanish Society of Cardiology


Subscribers of Revista Española de Cardiología

You may purchase this article for 30.00 €

Buy Now
Subscribers of ScienceDirect

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved